ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "lipids and rheumatoid arthritis"

  • Abstract Number: 469 • ACR/ARHP Annual Meeting 2013

    Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study

    Jaime Calvo-Alén1, Carmela Baamonde2, Ignacio Villa1, Víctor Martínez-Taboada3, Mario Agudo4 and Juan Gómez-Gerique5, 1Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, 2Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

    Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
  • Abstract Number: 1290 • ACR/ARHP Annual Meeting 2012

    Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis

    Christina Charles-Schoeman1, Roy Fleischmann2, Jean Davignon3, Howard Schwartz4, Scott Turner5, Carine Beysen5, Mark Milad6, Zheng Luo7, John Bradley8, Irina Kaplan8, Richard Riese7, Andrea Zuckerman7 and Iain B. McInnes9, 1University of California, Los Angeles, CA, 2Metroplex Clinical Research Center, Dallas, TX, 3University of Montreal, Montreal, Canada, 4Miami Research Associates, Miami, FL, 5KineMed Inc., Emeryville, CA, 6Milad Pharmaceutical Consulting LLC, Plymouth, MI, 7Pfizer Inc., Groton, CT, 8Pfizer Inc, Groton, CT, 9Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology